



WHO Guidelines Meeting on Preventive Therapy and Case Finding for TB in People Living with HIV.

25-27 January 2010
Kofi Anan Conference Room
World Health Organization, Geneva, Switzerland

Provisional Agenda

Day 1, Monday, 25 January 2010	08:30 -09:00	Registration	
	09:00 -09:15	Welcome Remarks	T. Guerma M. Raviglione
	09:15-09:30	Meeting overview and introductions	K. De Cock (Co-chair) H. Shünemann (Co-chair)
	09:30 -09:50	Rationale and review process of guidelines	R. Granich H. Getahun
	09:50 -10:00	Overview of GRADE methodology and review of PICOT questions for systematic reviews of scientific evidence	M. Penazzato
	10:00-10:30	<i>Coffee Break</i>	
	10:30-11:30	GRADE Profiles, systematic reviews and draft recommendations for PICOT Question 1: Define the optimal duration and drug regimen (e.g., INH, RIF, etc.) for treatment of LTBI to reduce the risk of developing Community commentary: Country/national programme commentary: Discussion: Open to the floor	M. Penazzato
	11:30-12:30	GRADE Profiles, systematic reviews and draft recommendations for PICOT Question 2: Define the optimal time to start considering IPT (i.e., should immune status be considered and should IPT be started with ART). Community commentary: Country/national programme commentary: Discussion: Open to the floor	M. Penazzato
	12:30-14:00	<i>Lunch</i>	

14:00-15:00	<p>GRADE Profiles, systematic reviews and draft recommendations for PICOT Question 3: Determine whether PLHIV who had received TB treatment in the past be provided secondary treatment of LTBI to prevent re-infection or recurrence of tuberculosis.</p> <p>Community commentary:</p> <p>Country/national programme commentary:</p> <p>Discussion: Open to the floor</p>	A. Sharma
15:00-16:30	<p>Working group session</p> <p>Group A/Picot 1 Optimal duration/drug regimen Group B/Picot 2 Optimal time to start Group C/Picot 3 Secondary treatment of LTBI</p>	
16:30-17:30	<p>Report back from Groups A, B, C:</p> <p>Group A/Picot 1 (15") Optimal duration/drug regimen Group B/Picot 2 (15") Optimal time to start Group C/Picot 3 (15") Secondary treatment of LTBI</p>	<p>K. De Cock (Co-chair) H. Shünemann (Co-chair)</p>



Day 2, Tuesday, 26 January 2010	09:00-09:10	Overview of Day 2	K. De Cock (Co-chair) H. Shuneman (Co-chair)
	09:10-10:00	<p>GRADE profiles, systematic reviews and draft recommendations for PICOT Question 4: Determine whether treatment for LTBI among PLHIV lead to significant developments of mono-resistance against the drugs used for LTBI treatment?</p> <p>Community commentary:</p> <p>Country/national programme commentary:</p> <p>Discussion: Open to the floor</p>	A. Sharma
	10:00-10:30	<i>Coffee Break</i>	
	10:30-11:30	<p>GRADE profiles, systematic reviews and draft recommendations for PICOT Question 5: Determine whether low adherence rates to LTBI treatment be a barrier to the implementation of LTBI treatment among PLHIV.</p> <p>Community commentary:</p> <p>Country/national programme commentary:</p> <p>Discussion: Open to the floor</p>	G. Russell
	11:30-12:00	<p>GRADE profiles, systematic reviews and draft recommendations for PICOT Question 6: Determine whether the provision of treatment for LTBI is cost-effective.</p> <p>Community commentary:</p> <p>Country/national programme commentary:</p> <p>Discussion: Open to the floor</p>	G. Russell
	12:00-12:30	<p>GRADE profiles, systematic reviews and draft recommendations for PICOT Question 7: PPD in resource-limited settings</p> <p>Community commentary:</p> <p>Country/national programme commentary:</p> <p>Discussion: Open to the floor</p>	C. Akolo
	12:30-13:30	<i>Lunch</i>	

13:30-14:30	<p>GRADE profiles, systematic reviews and draft recommendations for PICOT Question 8: Determine the best combination of signs, symptoms and diagnostic procedures (e.g., radiography, serum-based tests such as IGRA, etc.) as screening tools to determine eligibility for LTBI treatment and to diagnose TB among PLHIV? (Feasibility considerations included)</p> <p>Community commentary:</p> <p>Country/national programme commentary:</p> <p>Discussion: Open to the floor</p>	A.Date
14:30-15:30	<p>Working group session</p> <p>Group A/Picot 4+5 Resistance and adherence Group B/Picot 6+7 Cost-effective/PPD Group C/Picot 8 Signs, symptoms and diagnostics</p>	
15:30-15:45	<i>Working coffee</i>	
15:45-17:00	<p>Working group session (cont'd)</p> <p>Group A/Picot 4+5 Group B/Picot 6+7 Group C/Picot 8</p>	
17:00-18:30	<p>Report back from Groups A, B, C:</p> <p>Group A/Picot 4 +5 (20") Resistance and adherence Group B/Picot 6+7 (20") Cost-effective/PPD Group C/Picot 8 (20") Signs, symptoms/diagnostics</p>	<p>K. De Cock (Co-chair) S. Hill (Co-chair)</p>



Day 3, Wednesday, 27 January 2010	09:00 -09:15	Overview of Day 3	K. De Cock (Co-chair) S. Hill (Co-chair)
	09:15-10:00	Research priorities Report back from each group of research issues that emerged from working group discussion Group A (5") Group B (5") Group C (5")	K. De Cock (Co-chair) S. Hill (Co-chair)
	10:00-11:00	Wrap up of the major conclusions, recommendations	R. Granich H. Getahun
	11:00-11:30	<i>Coffee</i>	
	11:30-12:30	Closing and next steps	T. Guerma M. Raviglione
	12:30-13:30	<i>Lunch</i>	

DRAFT